You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 22, 2024

CLINICAL TRIALS PROFILE FOR SACUBITRIL; VALSARTAN


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Sacubitril; Valsartan

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01920711 ↗ Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction Completed Novartis Pharmaceuticals Phase 3 2014-07-18 The purpose of this study was to evaluate the effect of LCZ696 compared to valsartan in the reduction of cardiovascular death and heart failure(HF) hospitalizations in patients with HF with preserved ejection fraction.
NCT02554890 ↗ Comparison of Sacubitril/Valsartan Versus Enalapril on Effect on NT-proBNP in Patients Stabilized From an Acute Heart Failure Episode. Completed Novartis Pharmaceuticals Phase 4 2016-04-29 The purpose of this study was to assess the effect of in-hospital initiation of sacubitril/valsartan (LCZ696) vs. enalapril on time averaged proportional change in NT-proBNP in patients who have been stabilized following hospitalization for acute decompensated heart failure (ADHF) and reduced ejection fraction (left ventricular ejection fraction (LVEF) ≤ 40%).
NCT02636283 ↗ Use of Entresto Sacubitril/Valsartan for the Treatment of Peripheral Arterial Disease Terminated American Heart Association Phase 2 2017-12-31 This study proposes the use of Entresto (sacubitril/valsartan) to test the effects on pain free walking duration on patients with peripheral arterial disease, a condition caused by decreased blood flow to the muscles in the legs.
NCT02636283 ↗ Use of Entresto Sacubitril/Valsartan for the Treatment of Peripheral Arterial Disease Terminated University of Minnesota Phase 2 2017-12-31 This study proposes the use of Entresto (sacubitril/valsartan) to test the effects on pain free walking duration on patients with peripheral arterial disease, a condition caused by decreased blood flow to the muscles in the legs.
NCT02636283 ↗ Use of Entresto Sacubitril/Valsartan for the Treatment of Peripheral Arterial Disease Terminated University of Minnesota - Clinical and Translational Science Institute Phase 2 2017-12-31 This study proposes the use of Entresto (sacubitril/valsartan) to test the effects on pain free walking duration on patients with peripheral arterial disease, a condition caused by decreased blood flow to the muscles in the legs.
NCT02682719 ↗ Personalised Prospective Comparison of ARni With ArB in Patients With Natriuretic Peptide eLEvation Active, not recruiting Novartis Ireland Ltd Phase 2 2015-12-16 Sacubitril-valsartan, an Angiotensin Receptor Blocker-Neprilysin Inhibitor (ARNI), currently marketed for the management of heart failure, has been shown to reduce cardiovascular morbidity and mortality in stage C heart failure with reduced ejection fraction. In stage C HFpEF, sacubitril-valsartan has also been shown to reduce left atrial volume index measured using echocardiography over a 9 month timeframe. The PARABLE study investigates the hypothesis that sacubitril-valsartan can provide benefits in terms of left atrial structure and function as well as left ventricular structure and function in asymptomatic (stage A/B HFpEF) patients. This is a prospective, randomised, double-blind, double-dummy, phase II study design. The patient population will have hypertension and/or diabetes together with preserved ejection fraction, elevated natriuretic peptide (NP) and abnormal left atrial volume index (LAVI, > 28 mL/m2).
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Sacubitril; Valsartan

Condition Name

Condition Name for Sacubitril; Valsartan
Intervention Trials
Heart Failure 30
Hypertension 8
Heart Failure With Preserved Ejection Fraction 7
Cardiotoxicity 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Sacubitril; Valsartan
Intervention Trials
Heart Failure 57
Hypertension 7
Myocardial Infarction 6
Infarction 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Sacubitril; Valsartan

Trials by Country

Trials by Country for Sacubitril; Valsartan
Location Trials
United States 249
Spain 45
Italy 42
Japan 36
United Kingdom 35
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Sacubitril; Valsartan
Location Trials
Massachusetts 10
California 10
Virginia 9
Tennessee 9
Pennsylvania 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Sacubitril; Valsartan

Clinical Trial Phase

Clinical Trial Phase for Sacubitril; Valsartan
Clinical Trial Phase Trials
Phase 4 39
Phase 3 15
Phase 2/Phase 3 2
[disabled in preview] 29
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Sacubitril; Valsartan
Clinical Trial Phase Trials
Recruiting 35
Completed 21
Not yet recruiting 18
[disabled in preview] 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Sacubitril; Valsartan

Sponsor Name

Sponsor Name for Sacubitril; Valsartan
Sponsor Trials
Novartis Pharmaceuticals 20
Brigham and Women's Hospital 4
The Heartbeat Trust 3
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Sacubitril; Valsartan
Sponsor Trials
Other 117
Industry 27
NIH 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.